EU/3/01/055

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in April 2014 at the end of the period of market exclusivity.

On 18 September 2001, orphan designation EU/3/01/055 was granted by the European Commission to Lipomed GmbH, Germany, for cladribine (subcutaneous use) for the treatment of indolent non-Hodgkin's lymphoma.

Cladribine (subcutaneous use) has been authorised in the EU as Litak since 14 April 2004.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Cladribine
Medicine name
Litak
Disease / condition
Treatment of indolent non-Hodgkin's lymphoma
Date of first decision
18/09/2001
Outcome
Expired
EU designation number
EU/3/01/055

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in April 2014 at the end of the period of market exclusivity.

Sponsor's contact details

Lipomed GmbH
Hegenheimer Strasse 2
D-79576 Weil am Rhein
Germany
Tel +49 7621 1693 472
Fax +49 7621 1693 474
E-mail: lipomed@lipomed.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating